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ABSTRACT 
Diabetes is a group of diseases characterized by hyperglycaemia. Type 2 diabetes 
encompasses 85-95% of all diabetes with a prevalence that is expected to increase 
worldwide.   
In search of nutritional and dysmetabolic factors with potential impact on type 2 
diabetes this thesis focused on the risk of type 2 diabetes and prediabetes and 
association with wholegrain intake as well as effects of hyperglycaemia and 
dyslipidaemia on the function and survival of insulin secreting cells.  
We found in a population-based prospective study (Stockholm Diabetes Prevention 
Program) that low consumption of wholegrain was associated with an increased risk of 
deteriorating glucose tolerance. The strongest association was seen for individuals who 
at baseline had normal glucose tolerance (NGT) and at follow-up (8-10 years later) had 
progressed to prediabetes. Furthermore we confirmed effect modifications by 
polymorphisms of the TCF7L2 gene.  
An in vivo study of hyperglycaemic effects on beta cell mitochondrial morphology 
revealed that moderate hyperglycaemia induced larger, fewer and swollen 
mitochondria. These morphological effects on mitochondria could partially be inhibited 
by treatment with a KATP-opener. The morphological effects on mitochondria were 
reproduced in vitro and were linked to dysfunctional oxidative metabolism.   
Since diabetes is often accompanied by dyslipidaemia we aimed to study the effects of 
increased uptake of fatty acids and low-density lipoprotein (LDL) in insulin secreting 
cells. By overexpressing CD36 in an insulin secreting cell line (INS-1) we found that 
CD36 increased uptake of fatty acids. Overexpression of CD36 reduced the acute 
potentiating effect of fatty acids on glucose induced insulin secretion. Moreover modest 
effects on fatty acid oxidation and on the activity of carnitine palmitoyl transferase 1 
(CPT1) activity were found. CD36 overexpression also enhanced the uptake of 
oxidatively modified LDL (oxLDL) whereas the uptake of native LDL was not 
influenced. OxLDL dose-dependently decreased viability, however independently of 
CD36 overexpression. The result suggest that efficient cholesterol efflux counteracts 
potential toxicity by uptake of the lipoprotein and that extracellular signalling mediates 
the negative effects on viability by oxLDL 
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1 BACKGROUND 
1.1 DIABETES PREVALENCE, DIAGNOSIS AND CLASSIFICATION 
In 2011 the estimated prevalence of diabetes worldwide was 8.3% or 366 million 
people. The prevalence is expected to increase to 9.9% or 552 million people in the 
year 2030 [1]. 
Approximately 5-10% of all diagnosed diabetes in adults is categorised as type 1 
diabetes. Type 1 diabetes develops because of a loss of insulin production due to 
autoimmune reactions towards the pancreatic beta cells [2, 3]. Included in the type 1 
diabetes category is Latent Autoimmune Diabetes of the Adult (LADA) which is 
regarded a slowly progressing autoimmune form of diabetes [4]. 
Type 2 diabetes accounts for 85-95% of all diagnosed diabetes [2, 3, 5]. Development 
of type 2 diabetes is due to the body’s ineffective use of insulin caused by insulin 
resistance as well as deficient insulin secretion [5]. 
Other types of diabetes include monogenetic diseases (maturity onset diabetes of the 
young, MODY), mitochondrial diabetes [6] as well as gestational diabetes [7]. Diabetes 
can also result from other endocrine diseases, infections, medications, surgery and 
pancreatic disease [2, 8]. 
Complications of diabetes include damages to nerves and blood vessels; hence diabetes 
is a serious cause of kidney failure, amputation and blindness [5]. 
An intermediate stage between normal glucose regulation and diabetes is referred to as 
‘impaired glucose regulation’. This stage includes impaired glucose tolerance (IGT) 
and impaired fasting glycaemia (IFG) [7]. Table 1 summarises the 2006 WHO 
recommendations for the diagnostic criteria for diabetes, and intermediate 
hyperglycaemia (IGT and IFG) [9]. 
IGT and IFG are often referred to as prediabetes since these conditions are often seen 
before a diabetes diagnosis is reached. Approximately 70% of subjects with prediabetes 
have been reported to eventually develop diabetes [10]. 
Inadequate insulin secretion and insulin resistance are the two conditions that separately 
or combined cause all forms of diabetes. An overview of insulin secretion is presented 
below, followed by a description of insulin action. 
 
Table 1. Adapted from 2006 WHO recommendations for the 
diagnostic criteria for diabetes and intermediate hyperglycaemia 
Diabetes 
Fasting plasma glucose 
2 h plasma glucose* 
 
≥ 7.0 mmol/l or  
≥ 11.1 mmol/l 
Impaired Glucose Tolerance (IGT) 
Fasting plasma glucose 
2 h plasma glucose* 
 
< 7.0 mmol/l and 
≥ 7.8 and < 11.1 mmol/l 
Impaired Fasting Glycaemia (IFG) 
Fasting plasma glucose 
2 h plasma glucose* 
 
6.1 to 6.9 mmol/l and (if measured) 
< 7.8mmol/l 
* Venous plasma glucose 2 h after a 75 g oral glucose load. If 2 h plasma glucose is not 
measured, status is uncertain as diabetes or IGT cannot be excluded. Adapted from 
reference [9]. 
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1.2 BETA CELL FUNCTION AND METABOLISM 
1.2.1 Insulin biosynthesis  
Biosynthesis of insulin starts with the synthesis of preproinsulin, a single-chain 86 
amino acid precursor polypeptide, on the polyribosomes associated with the rough 
endoplasmic reticulum (RER) [11]. Preproinsulin is translocated into the RER lumen 
and proteolytic processing removes the amino-terminal signal peptide resulting in 
proinsulin. Proinsulin forms di-sulfide bounds to uphold tertiary structure and is 
transported through the Golgi where it chelates with Zn
2+
 (hexamers). Finally an 
immature granule is formed. Within the immature granule proinsulin is further cleaved 
into the connective-peptide (C-peptide) and the A and B chains of insulin generating 
the mature granule. It is these newly formed mature granules that are secreted upon 
stimulation. 
Approximately 1 % of the total insulin content is secreted upon glucose stimulation per 
hour while the remaining pool is constantly turned over (half-life 3-5 days). If demands 
of insulin increase, (as in type 2 diabetes) more immature granules will be secreted and 
hence also increased amounts of unprocessed proinsulin. Proinsulin biosynthesis is 
regulated by the different secretagogues such as glucose, amino acids, fatty acids and 
glucagon-like peptide 1 (GLP-1) [11]. 
 
1.2.2 Insulin secretion 
1.2.2.1 Glucose 
A simplified schematic model of insulin secretion is illustrated in figure 1. Glucose 
enters the beta cells by facilitated diffusion through glucose transporters (GLUT 1, in 
humans, GLUT 2, in rodents) [8, 12]. Intracellular glucose is phosphorylated by 
glucokinase (GK) (rate limiting step) to glucose-6-phosphate (G6P). G6P is then further 
metabolised through glycolysis into pyruvate. 
 
Pyruvate enters the mitochondria and is further metabolised by either pyruvate 
carboxylase (PC) for the anaplerosis/cataplerosis pathway into oxaloacetate or by 
pyruvate dehydrogenase (PDH) for the glucose oxidation pathway into acetyl-CoA. 
Both these actions enhance mitochondrial tricarboxylic acid (TCA) cycle activity, 
thereby generating ATP. This causes the cytosolic ATP/ADP ratio to increase which in 
turn induces closure of ATP-sensitive potassium channels (KATP-channels) [13]. 
 
The KATP-channel is an octameric complex of two protein subunits; four regulatory 
proteins, sulfonylurea receptor 1 (SUR1), and four pore forming subunits (Kir 6.2) [14]. 
ATP binds to the Kir 6.2 subunit and closes KATP-channels [14]. Sulfonylureas, a 
category of drugs used in diabetes treatment, bind to SUR1 and increase the ATP-
sensitivity of Kir 6.2. On the other hand KATP-channel openers such as diazoxide or 
tifenazoxide (used in the present thesis) inhibit insulin secretion by opening (thus 
inhibiting closure) of the channel [14]. 
 
Closure of KATP-channels leads to membrane depolarisation and opening of voltage 
dependent Ca
2+
-channels which facilitates extracellular Ca
2+
 to enter the cell. In the 
secretory process insulin secretory granules are mobilised towards the plasma 
membrane, then fuses with it, thereby releasing insulin [8].  
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A rise in cytosolic Ca
2+
 initiates the exocytosis of insulin granules. Granules docking at 
the cell membrane and the exocytosis processes can be further influenced by glucose 
metabolism through activation of phospholipase C (PLC) which in turn promotes 
hydrolysis of phospholipids and formation of inositol 1,4,5-triphosphate (IP3) which 
can stimulate Ca
2+  
release from the endoplasmic reticulum (ER). Activation of PLC 
also generates diacylglycerol (DAG) which stimulates protein kinase C (PKC) which in 
turn also increases Ca
2+
. Glucose metabolism can also activate adenylate cyclase (AC) 
and further protein kinase A (PKA) through cyclic AMP (cAMP) [15].  
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1.2.2.2 Other secretagogues 
Of the nutrients the beta cells are most sensitive to glucose. However other nutrients 
such as fatty acids and amino acids can also initiate or amplify insulin secretion, see 
figure 1. 
Glutamine and alanine are quantitatively the most abundant amino acids in the blood. 
Amino acids at physiological concentrations do not individually induce insulin 
secretion. However supra-physiological concentrations or a combination of amino acids 
are able to induce insulin secretion and potentiate glucose-induced insulin secretion. 
The mechanisms for how amino acids stimulate insulin secretion are complex and 
partly include mitochondrial metabolism. Alanine (via pyruvate) increases production 
of ATP thus stimulating the KATP-channel dependent pathway. Alanine also acts 
directly on the depolarisation of the membrane as an electrogenic amino acid through 
co-transportation by Na
+
 causing the influx of Ca
2+
. Glutamine can in combination with 
leucine promote insulin secretion through several complex mitochondrial mechanisms. 
Arginine in supra-physiological concentrations can depolarise the membrane by acting 
as a cationic amino acid. Alanine and glutamine have also been shown to alter and 
regulate gene expression of several genes involved in metabolism [16, 17]. 
 
Acute exposure to fatty acids (FA) potentiates glucose induced insulin secretion both in 
vivo [18, 19] and in vitro [20]. The effect is dependent on the unbound fraction rather 
than the total concentration. Saturated fatty acids are more potent than unsaturated [21]. 
The mechanisms by which fatty acids stimulates insulin secretion could be several such 
as amplifying activation of the secretory machinery, activation of protein kinase C [22], 
or binding/activation to G coupled protein 40 (GPR40) and subsequent signalling [23]. 
The potentiating effect of acute FA in glucose induced insulin secretion is not 
persistent. Instead long term stimulation of fatty acids results in decreased glucose 
induced insulin secretion [18]. Multiple mechanisms, not fully elucidated have been 
proposed. Mechanism have been linked to ER-stress, apoptosis, effects on proinsulin 
biosynthesis and disturbed interplay between nutrient metabolism and other circulating 
factors influencing mitochondrial function [13, 24, 25]. 
 
1.2.2.3 Other signalling  
Oral glucose administration amplifies insulin secretion compared to intravenous 
infusion of glucose in healthy subjects. This is due to the incretin effect. Incretins are 
hormones released from the gastro-intestinal tract into the circulation after food 
ingestion. For glucose homeostasis the most important incretins are GLP-1 which is 
secreted from the L-cells localized in the ileum and the colon and glucose-dependent 
insulinotropic polypeptide (GIP) which is secreted from the K-cells localized in the 
duodenum and proximal jejunum [26, 27]. GLP-1 agonists (used in the treatment of 
type 2 diabetes) slow gastric emptying, increase satiety and promote modest weight 
loss and are in preclinical studies suggested to improve beta cell function, lower blood 
pressure and improve cardiovascular outcomes [27]. 
 
Other signalling for insulin secretion operates through the parasympathetic nervous 
system which can enhance both insulin and glucagon secretion by stimulation of the 
vagus nerve. Activation of the sympathetic nervous system can inhibit basal and 
glucose-induced insulin secretion [26]. 
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Other islet hormones also come into play for glucose regulation. Glucagon, which is 
secreted from the alpha cells of the islets of Langerhans, stimulates glucose production 
in the liver both by gluconeogenesis and glycogenolysis. These effects are important 
for maintaining glucose homeostasis during a fasting state. Somatostatin, secreted from 
the delta cells of the islet of Langerhans, can decrease the small intestinal transit time 
and also inhibit the secretion of insulin and glucagon. Furthermore other incretins or 
gastro intestine polypeptides can affect the secretion of glucagon and somatostatin [26, 
27]. 
 
1.2.3 Role of mitochondria for beta cell function 
The mitochondrion is a double-membrane organelle responsible for energy supply 
mainly in the form of ATP. It has a circular deoxyribonucleic acid (DNA) which is 
maternally inherited and contains 37 genes. These genes are transcribed within the 
mitochondria into some of the components of the respiratory chain complexes. Other 
components of respiratory chain complexes are synthesized in the cytosol by nuclear 
DNA (nDNA) and transported into the mitochondria [28]. 
 
Mutations in mitochondrial DNA (mtDNA) have been linked to maternally inherited 
forms of diabetes [29]. Mitochondria in the beta cells are especially important 
compared to other cell types since they are the ultimate sensor of glucose homeostasis 
and couples metabolism to insulin secretion. Beta cell glycolysis generates higher 
proportions of pyruvate compared to other cells because the lactic dehydrogenase 
enzyme levels are low. The replenishment of carbons both in the form of acetyl-CoA 
and in the form of oxaloacetate and subsequent oxidation activates the electron transfer 
in the respiratory chain with the final production of ATP. A rise in cytosolic ATP levels 
then acts as a signal for insulin secretion [28]. 
 
Mitochondria continuously divide and fuse with other mitochondria. Several proteins 
are known to be involved in these fission and fusion events. Of proteins involved there 
has been much focus on mitofusion protein 1 and 2 (Mfn1, Mfn2). These proteins are 
GTPases associated to the outer cell membrane which has been suggested to be 
involved in the outer membrane fusion. Optic atrophy 1 (OPA1), a dynamin GTPase 
located in the intermembrane space and also associated with the inner membrane has 
been suggested to be involved in the inner membrane fusion [30, 31]. For fission the 
most important protein may be the dynamin related protein 1 (Drp1) which is located in 
the cytosol and is thought to be involved in the constriction of mitochondria fission [30, 
31]. Mitochondrial morphology depends partly on a balance between fusion and 
fission. Mutations in the OPA1 and Mfn2 have thus been associated with dysfunction. 
Additionally both fission and fusion are involved in early stages of apoptosis and in 
particular mitochondrial fragmentation [31]. 
 
In the transport of electrons in the respiratory chain there is always a small leakage of 
oxygen. This oxygen can form reactive oxygen species (ROS). It has been speculated 
that the ROS formation adjacent to the mtDNA could be involved in the accumulation 
of mtDNA damage including mutations. Mutations could subsequently lead to 
increased ROS formation, a notion which is part of the ageing hypothesis [31, 32]. Beta 
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cells have been shown to have less of the enzymes handling ROS such as catalase or 
glutathione peroxidase [33] and also lack protective histones [34]. Beta cells would 
then be particularly sensitive to ROS induced damage compared to other tissues. It is in 
any case clear that functioning mitochondria is a prerequisite for functioning insulin 
secretion and glucose homeostasis. 
With the progression of type 2 diabetes when glucose homeostasis declines and 
metabolic control worsens, mitochondria are subjected to glucotoxicity, i.e. negative 
effects of hyperglycaemia (more detailed in 1.4.4). Abnormal mitochondria 
morphology has been found in islets from type 2 diabetes patients [35]. Potential 
mitochondrial effects of glucotoxicity remain to be fully elucidated. 
 
1.2.4 Role of lipids for beta cell function 
1.2.4.1 General function and transport 
Lipids assist important biological functions in the body e.g. transport of lipid soluble 
vitamins. Furthermore phospholipids and cholesterol are important for maintaining cell 
integrity, as they are part of cell membranes. When transported in plasma lipids they 
also serve as energy substrates and in the exchange of energy storage places [36, 37]. 
They act as mediators via prostaglandins and leukotrienes, and act as ligands for gene 
transcription [36]. 
Transport of free fatty acids in plasma occurs to major part with fatty acids bound to 
albumin [38] although a small fraction is unbound. Fatty acids can enter cells by 
passive diffusion over the cell membrane or by facilitated transport with membrane 
transport proteins. Several of the transport proteins have been extensively studied in 
various tissues [39-41]. 
CD36, also called fatty acid translocase (FAT), is one of the most important proteins 
involved in fatty acid uptake by cells. CD36 is an 88 kDa trans-membrane protein 
which is heavily glycosylated, see figure 2 [42]. CD36 is involved in many functions 
because of its wide expression and broad specificity [43, 44]. It is thus also involved in 
binding of oxLDL, in phagocytosis and in toll-receptor signalling [45]. CD36 is 
expressed in many different cell types such as monocytes, macrophages, muscle cells, 
adipocytes and pancreatic beta cells etc. [40, 42, 43].  In non-beta cells it has been 
shown to facilitate the major uptake of long-chain fatty acids [46]. 
CD36 facilitated fatty acid uptake is suggested to take place in caveolae which are 
formed in lipid rafts however data are not conclusive [47]. In beta cells, CD36 was 
found in the plasma membrane as well as intracellular and co-localized with insulin 
granules [40]. Little is known about expression and trafficking of CD36 in cell 
organelles. Variations in CD36 expression have been found both in vitro and in vivo to 
influence fatty acid metabolism [48]. Since CD36 is widely expressed the interpretation 
of the regulation of its expression is complex. A number of cell lines and animal 
models have been used to study the effects of altered CD36 expression [48] but few 
studies have been made in insulin secreting cells. 
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Figure 2. Predicted hairpin topography of CD36 protein in the plasma membrane. 
CD36 extracellular domain has multiple glycosylation sites, a proline-rich domain and 
an internal hydrophobic sequence. The N- and C-terminus in the cytosolic domain has 
several palmitoylation and ubiquitination sites. Palmitoylation are suggested to be 
involved in recruitment of CD36 and ubiquitination sites are sensitive for fatty acids 
and insulin suggested to play a role in the turnover of CD36. 
Figure is from Su X and Abumrad N.A. Cellular fatty acid uptake: a pathway under 
construction. Trends in Endocrinology & Metabolism 2009:20(2):72-77 [42]. 
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When fatty acids are transported into the beta cells they are transformed by acyl-CoA 
synthase (ACS) into long-chain acyl CoA. When glucose levels are low, long-chain 
acyl-CoA are transported into the mitochondria by carnitine palmitoyl transferase 1 
(CPT1) for beta oxidation. When glucose levels are high, glucose metabolism in the 
tricarboxylic acid (TCA) cycle produces citrate which can be transported to the cytosol 
and converted into malonyl-CoA by acetyl-CoA carboxylase (ACC). Malonyl-CoA 
inhibits CPT1 and thus transport of long-chain acyl-CoA to mitochondria [13], see 
figure 1. 
Furthermore malonyl-CoA formation from acetyl-CoA is inhibited by the AMP-
activated protein kinase (AMPK) (activated when AMP increases, in low glucose 
levels) inhibiting the acetyl-CoA carboxylase [13]. 
In order to move water insoluble molecules, i.e. triglycerides and cholesterol, through 
the blood and inside and outside of cells, both proteins and lipids are assembled into 
structures called lipoproteins. Low-density-lipoprotein (LDL) consists of triglycerides 
and cholesteryl ester molecules in its core; unesterified cholesterol molecules, of which 
approximately one-third lies in the core and two-thirds reside on the surface; a surface 
monolayer of phospholipid molecules; and a single copy of apolipoprotein B-100 
(ApoB100) [49]. 
The transport of lipids by lipoproteins in plasma is tightly regulated through hormonal 
and metabolic control that influences synthesis/assembly and catabolism/clearance of 
these particles in different organs. Furthermore carbohydrate and lipid metabolism are 
intertwined and the lipoprotein lipase (LPL) and hormone sensitive lipase (HSL) are 
partly regulated by insulin and catecholamines [8]. 
 
1.3 INSULIN ACTION 
Insulin is transported in the circulation to peripheral tissues (most importantly muscle, 
fat and liver) where it stimulates the uptake of glucose, resulting in normalisation of 
blood glucose levels. This regulation of blood glucose levels is necessary since both 
hypoglycaemia (acute) and hyperglycaemia (long-term) are detrimental. Insulin 
resistance (a common feature in type 2 diabetes patients) in the peripheral tissues 
means that more insulin than normal is required for cells to take up glucose. Because of 
insulin resistance the demands for insulin grow higher until beta cells are unable to 
meet the demands. The tightly controlled blood glucose regulation is then lost and 
hyperglycaemia prevails and leads to further deterioration of insulin secretion [8]. 
 
1.4 RISK FACTORS AND DYSMETABOLIC FACTORS INVOLVED IN 
TYPE 2 DIABETES  
Genetic, intra-uterine conditions as well as post-natal environmental factors are 
involved in the development of type 2 diabetes. Both insulin sensitivity and insulin 
secretion are affected [8]. 
 
1.4.1 Genetic factors and family history of diabetes  
Individuals with a family history of diabetes have a two to four fold increased risk of 
developing diabetes compared to individuals without family history of diabetes. The 
risk is depending on number of relatives with diabetes and how close these relatives are 
[50]. Family history of diabetes as a risk factor can partly be explained by shared genes 
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but also by shared environment. However, there is no doubt that there is a strong 
genetic component in type 2 diabetes. 
Genetic association studies have found a number of genes (36-44 genes) associated to 
type 2 diabetes however the effect size is low. Most of the diabetes-associated genes 
involve the function of beta cells rather than insulin resistance [51, 52]. 
One of the strongest associations was found for gene variants in TCF7L2 [51]. Two 
Scandinavian prospective cohort studies showed that carriers of risk allele T in single 
nucleotide polymorphism (SNP) rs7903146 increased the risk for diabetes by 60%. 
These studies found an association to enhanced expression of TCF7L2 in human islets, 
in addition to impaired insulin secretion [53]. Variation in TCF7L2 influences the 
efficacy of sulfonylureas (SU) which are drugs promoting insulin secretion; subjects 
with risk allele were less likely to respond to SU.  TCF7L2 risk allele did not influence 
the efficacy of metformin (a drug enhancing the insulin sensitivity) [54]. 
TCF7L2 polymorphisms have been associated with certain phenotypic parameters such 
as impaired insulin secretion, beta cell function and GLP-1 potentiation of insulin 
secretion [55]. TCF7L2 has also been suggested to modify the risk for type 2 diabetes 
association to carbohydrate quality and quantity [55]. Such a modifying effect of 
TCF7L2 has however been disputed, [56] emphasizing the need for further studies. 
 
1.4.2 Intra-uterine conditions 
Intra-uterine risk factors are related to intra-uterine growth retardation and low birth 
weight [57, 58]. Intrauterine growth retardation was also associated with hypertension 
which could explain the association between hypertension and diabetes [57, 59]. 
Intrauterine environment caused by gestational diabetes is also a risk factor for diabetes 
in the offspring [58, 59]. 
 
1.4.3 Environmental factors  
1.4.3.1 Overweight and physical inactivity  
Overweight or obesity is considered one of the strongest predictors of type 2 diabetes 
[58, 60]. The risk of diabetes is strong whether measured by increased waist 
circumference, waist to hip ratio or BMI [60-63]. Obesity is a heterogeneous disease 
where several genes have been identified with susceptibility loci. One of the most 
studied is the ‘fat mass and obesity associated protein’ (FTO) [64]. Although there is a 
genetic component in obesity the risk can be modified by environmental factors such as 
physical activity [65]. In fact epidemiological studies indicate a 30-50% reduced risk of 
developing diabetes in physical active individuals (overweight and normal weight) 
compared to physical inactive individuals [66]. 
 
1.4.3.2 Dietary factors  
The increasing incidence of type 2 diabetes occurs in the societies where there has been 
a major shift towards a more inactive lifestyle and rapid changes in the dietary patterns 
both with regards to availability and with more energy dense diet [59].  Numerous 
studies have looked for dietary risk factors for development of diabetes, yet convincing 
evidence for population based guidelines are scarce.  
A high intake of saturated fat has been associated with a higher risk for impaired 
glucose tolerance in epidemiological observational studies [59, 67]. Higher levels of 
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saturated fatty acids in serum lipids and in muscle phospholipids were associated with 
increased levels of fasting glucose and decreased insulin action [59, 68, 69]. 
Interventions studies with replacement of saturated with unsaturated fatty acids 
improved glucose tolerance and enhanced insulin sensitivity [70]. 
Among other dietary factors that can modify the risk for type 2 diabetes, dietary fiber 
and wholegrain have gained a lot of attention. 
Definition of dietary fiber has varied over the years and in different countries. 
Previously the terms soluble and insoluble dietary fiber was used to explain physical 
effects. However these terms are less used today. Clarification of the current definition 
of fiber can be found in ref [71]. Briefly; non-starch polysaccharides (such as cellulose, 
hemicellulose, pectins and other hyrocolloids) are the main constituent of dietary fiber. 
Dietary fiber also includes resistant starch, resistant oligosaccharides and dietary 
associated lignin. These are all non-digestible carbohydrates, i.e. they are resistant to 
hydrolysis and absorption in the small intestine. Instead insoluble fibers, (mainly from 
wholegrain) undergo anaerobic fermentation in the colon by bacteria with the 
production of short-chain fatty acids (SCFA) which could then be used as energy 
substrate by the mucosa in the colon [71]. These SCFA could also have effect on 
hepatic glucose output [72, 73]. Soluble form of fibers (mainly from fruit and 
vegetables) have effects on gastric emptying and gastric transit time, and thereby the 
glucose response [73].  Average intake of dietary fiber in adults is 15-30 g/day while 
the recommended dietary intake varies between 25-45 g/day [71]. In Sweden only 5-
10% of adults reach the recommended intake [74]. 
Wholegrain is not a nutrient as such, but generally considered as a food group. 
Wholegrain is an important contributor of fiber intake. Wholegrain is generally defined 
as grains that consist of the intact, ground, cracked or flaked caryopsis whose principal 
anatomical components, the starchy endosperm, germ and bran, are present in the same 
relative proportions as they exist in the intact caryopsis. Wholegrain foods or 
wholegrain products are however differently defined in different countries [75]. 
A cohort by Liese et al. 2005 [76] found that intake of fiber was positively associated 
with insulin sensitivity and negatively associated to fasting insulin levels. Dietary fiber 
was also negatively associated with the probability of having insulin resistance 
(measured by HOMA-IR) [77]. Prospective studies have found that increasing intake of 
whole grain [78, 79] and cereal fiber [73, 80-82] resulted in decreased risk of type 2 
diabetes. Other prospective studies have showed low intake of fiber, mainly cereal 
fiber, to increase the risk of type 2 diabetes [83, 84]. Not all studies found an 
association of diabetes risk and total fiber intake. Therefore it is still to be established if 
the wholegrain or the cereal fiber (mostly insoluble fiber) or the fruit and vegetables 
(mostly soluble fibers) provides the beneficial effects [71]. Further studies on 
individuals with type 2 diabetes and whether fiber rich diets could improve glycaemic 
control are needed. Some intervention studies suggest an effect of the soluble fiber 
rather than the insoluble [58]. Of the two nutrients described, (saturated fat and dietary 
fiber), the effect of fiber is more documented. However more prospective studies are 
needed on the importance of wholegrain for effects on insulin resistance and 
development of diabetes. Wholegrain and possible gene interactions also warrant 
further studies as they are contradictory [56, 85]. 
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1.4.4 Effects of hyperglycaemia 
Chronic hyperglycaemia has been shown to have detrimental effect on insulin secretion 
and insulin action. Improving metabolic control in type 2 diabetic patients improves 
insulin secretion [86]. This provides one piece of evidence that chronic hyperglycaemia 
in itself exerts negative effects on glucose homeostasis. A reduced insulin resistance in 
type 2 diabetes patients after improvement in metabolic control has also been 
demonstrated [8]. 
Mechanisms studied implicate oxidative stress as a large contributor to these 
detrimental effects. Hyperglycaemia in vitro for 3 days increased rat islet apoptosis, 
cytoplasmic DNA fragmentation and caspase-3 activity. Furthermore gene expression 
of pro-apoptotic proteins increased while gene-expression of anti-apoptotic proteins 
decreased [87]. Another mechanism involves the impairment of insulin gene expression 
[88]. Glucotoxicity has also been shown to induce ER-stress [89]. Mechanism behind 
induction of insulin resistance include a number of biochemical disturbances in insulin 
signalling [8]. 
Long term hyperglycaemia is known to desensitize beta cells to glucose-induced insulin 
secretion as shown in glucose-infused rats [90]. This desensitization could be avoided if 
insulin secretion was blocked by KATP opener [91]. It was proposed that the 
desensitization effect of hyperglycaemia was secondary to overstimulation of the beta 
cells [91]. 
To separate the effects of hyperglycaemia (glucotoxic effects) from overstimulation a 
transplant study was made in moderately hyperglycaemic animals [92]. Transplants of 
islets to moderately hyperglycaemic animals were combined with treatment of KATP 
openers. This procedure resulted in beneficial effects on insulin secretion which could 
not be explained by effects of insulin content or beta cell number [92]. 
To follow up on these findings it seemed important to investigate effects on 
mitochondria of chronic hyperglycaemia and the modifying effects of KATP openers. 
 
1.4.5 Dyslipidaemia 
1.4.5.1 General 
Diabetes confers an increased risk of cardiovascular disease and mortality [93]. 
Abnormalities of lipids and lipoproteins such as high triglycerides, low high density-
lipoproteins (HDL) and increased concentration of LDL-cholesterol particles are often 
found in patients with diabetes [94]. Prevalence of hypercholesterolemia (total) is not 
increased in patients with type 2 diabetes, nevertheless mortality increases 
exponentially with serum cholesterol levels [94].  
Causes for dyslipidaemia have both genetic and environmental components. There are 
a number of monogenic and polygenic disorders that influence lipid metabolism. Other 
genetic variants require environmental influence in order to achieve clinical 
manifestations [95]. Pathogenesis of diabetic dyslipidaemia is well studied and 
suggested to be coupled to insulin resistance. With insulin resistant fat cells the 
circulation of free-fatty acids increases which enhances the production of very low-
density lipoprotein (VLDL) in the liver [94]. Hyperinsulinemia (secondary to insulin 
resistance) also affects lipid exchange between different lipoproteins, generating 
increased concentrations of small dense LDL particles and reduced levels of HDL 
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cholesterol [94]. Dyslipidaemia as in diabetes is also common in prediabetes. Hence 
dyslipidaemia can exist long before glycaemic control is lost [96]. 
 
1.4.5.2 Fatty acid and lipoprotein interaction with beta cells under normal and 
diabetic conditions 
As mentioned previously, fatty acids influence beta cell function. Acute exposure to 
fatty acids thus potentiates insulin secretion, while long term exposure can reduce 
insulin secretion.  
Lipoprotein involvement in cardiovascular diseases is well established and 
atherosclerotic effects of oxLDL have been in focus [97]. The effect of oxLDL in 
development of diabetes is however largely unknown. Patients with type 2 diabetes 
have been found to have higher levels of serum oxLDL than controls and these levels 
increased with duration of type 2 diabetes [98]. LDL was found to be taken up by rat 
and human beta cells [99] via an LDL receptor [100]. Uptake of oxLDLs has in other 
tissues been shown to occur via scavenger receptors such as CD36 [44]. OxLDL has 
been shown to reduce insulin secretion in insulin secreting cell lines caused by reduced 
preproinsulin mRNA expression [101, 102]. 
However, there is discrepancy on whether native LDL and oxLDL affects the function 
of beta cells or whether the lipoproteins cause necrosis or apoptosis [100, 102, 103]. 
Also the importance of cellular uptake of lipoproteins for negative the effects has not 
been elucidated. Thus further studies are warranted.  
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2 AIMS  
 
The overall objectives of this thesis was first, to study the impact of certain nutritional 
risk factors on the progression to abnormal glucose tolerance and next to study the 
influences of type 2 diabetes associated conditions of dysmetabolism in insulin-
secreting cells. 
 
Specific aims for the individual studies 
 
Study I 
To test in a prospective population-based cohort for associations between intake of 
fiber and wholegrain and the risk of developing abnormal glucose tolerance, including 
prediabetes and type 2 diabetes, and to test for modulation by polymorphisms of the 
TCF7L2 gene. 
 
Study II 
To examine in beta cells the impact of a diabetic state with hyperglycaemia on 
morphometry of mitochondria and relate in vivo findings with glucose effects in vitro 
as well as modifying influence of KATP opener. 
 
Study III  
To investigate how overexpression of CD36 in insulin producing cells affects cellular 
localisation of CD36, uptake and efflux of fatty acids, insulin secretion and oxidative 
metabolism. 
 
Study IV 
To investigate if CD36 in insulin producing cells potentially scavenges oxLDL and 
further to study whether enhanced scavenging affects function. 
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3 MATERIAL AND METHODS 
 
3.1 SUBJECTS AND STUDY DESIGN 
The first study is based on a population-based cohort of Stockholm Diabetes Prevention 
Program (SDPP) illustrated in figure 3. All participating subjects gave their informed 
consent and the study has been approved by the ethics committee of Karolinska 
University Hospital. 
 
3.1.1 Baseline study 
Subjects (ages 35-56 years) were invited to the study in the years 1992-1994 (men) and 
1996-1998 (women) from four (men) or five (women) municipalities in Stockholm 
County. Subjects answered a short questionnaire about country of birth and whether 
they or their relatives had diabetes. Response rate was 79% for men and 85% for 
women. From these 47% (men) and 50% (women) were excluded due to; prior 
diabetes, other country of birth, unclear or insufficient family history of diabetes 
(FHD). Positive FHD, which was self-reported by the subjects, was classified as 
follows; at least one first-degree relative (parent or sibling) or at least two second-
degree relatives (grandparents, uncles or aunts) with diabetes onset later than 35 years 
of age. 
The sample was enriched to approximately 50% with subjects having positive FHD and 
they were matched to subjects having negative FHD by age and municipality. These 
subjects were invited to the first health examination which included an oral glucose 
tolerance test (OGTT) (2 h, 75 g), body measurement such as length, weight, waist/hip 
circumference, blood pressure and an extensive questionnaire. The questionnaire 
included questions on tobacco and alcohol consumption, physical activity, education, 
socio-economic and psychosocial factors and dietary habits. Excluded after first health 
examination were subjects with incomplete examinations, pregnancy, breastfeeding, 
and certain medical conditions. Finally baseline study comprised of 3128 men and 4821 
women. 
 
3.1.2 Follow-up study 
Baseline study was followed up 8-10 years later and subjects were invited to a second 
health examination. Excluded from this invitation were subject who either 1) moved 
out of Stockholm County, 2) who died during the follow-up period or 3) who already at 
baseline were diagnosed with diabetes. The invited subjects underwent a similar health 
examination and questionnaire as at baseline. Those who were diagnosed with diabetes 
during the follow-up period were excluded from the OGTT. Instead for these subjects a 
fasting blood sample was drawn and subjects were asked about year of diagnosis and 
type of treatment. In the end 2383 men and 3329 women representing 76% and 69% of 
the baseline subjects were included in the follow-up study. 
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Figure 3. Study design. Baseline and follow-up study of men and women in Stockholm 
Diabetes Prevention Program. FHD (family history of diabetes). *Excluded due to 
already known diabetes, foreign origin, unclear or insufficient FHD. ** Excluded due 
to diagnosis of diabetes at baseline examination, moved outside Stockholm county or 
deceased. 
 
3.1.3 Classification of glucose tolerance  
Glucose tolerance was classified according to WHO statement (see Table 1) and 
subjects were identified as having either normal glucose tolerance (NGT), impaired 
fasting glucose, impaired glucose tolerance or type 2 diabetes [9]. Pre-diabetes was 
classified as either IFG or IGT or the combination of the two. Glucose was analysed by 
glucose oxidase method and insulin and proinsulin was assayed by radioimmunoassays 
 16 
 
[104]. Proinsulin data at baseline was available for men only and levels (in pmol/L) and 
the ratio of proinsulin/insulin in per cent were calculated. 
 
3.1.4 BMI, HOMA-IR and insulin response calculations 
Relative change in body mass index (BMI) between baseline and follow-up was 
calculated in per cent. The median value of BMI change, based on the distribution 
among all subjects, was used to dichotomize the sample. 
                                 ( 
           
           
)      
The homeostasis model assessment [105] was used to assess insulin resistance 
(HOMA-IR) calculated as 
        
                               
    
 
Insulin response was estimated in two ways: as beta-cell function (HOMA- beta) 
calculated as 
                             
                   
 
or from the difference between 2 h and 0 h plasma insulin values from the OGTT 
(insulin-response(2h-0h)) 
                        (  )         (  ) 
 
3.1.5 Dietary fiber and wholegrain  
The dietary food-frequency questionnaire (FFQ) was primarily designed to evaluate fat 
and fiber intake. This questionnaire has previously been validated by a 7-day weighted 
record in a similar subgroup of men [106]. All food items in the FFQ contributing with 
fiber were analysed in our study. The eight frequency response options were; at least 4 
times/day, 2-3 times/day, once/day, 4-6 times/week, 2-3 times/week, once/week, 1-3 
times/month and seldom or never. To assess fiber intake in gram per day the food 
database (version 2011-07-18) at the Swedish National Food Agency [107] and a 
standard portion size/serving of the food items was used. As the FFQ was specifically 
aimed to assess fiber and fat we were not able to assess the total energy intake. 
The food database also provides data on wholegrain content. This allowed us to 
calculate the total wholegrain intake. In these calculations we included all food items 
that contained at least 18 g wholegrain per serving, i.e. crisp bread, wholemeal bread, 
oatmeal and muesli. 
To evaluate whether the intake of fiber and wholegrain varied over time we also 
calculated fiber and wholegrain intake from follow-up data. These calculations were 
performed in the same way as for baseline data. 
Intake of wholegrain and fiber was categorized into tertiles according to the distribution 
among all included subjects or used as continuous variables, reported as a decrease by 
30 g/day (wholegrain) or 10 g/day (fiber). 
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3.1.6 Established risk factors and potential confounders 
Age was included as continuous variable. Family history of diabetes (FHD) was 
dichotomized as either positive or negative, (for classification se section on baseline 
study). BMI ( kg/m
2
) was used as a continuous variable or in three groups (<25.0, 25.0-
29.9, and ≥30.0) for baseline characteristics.  Physical activity was assessed based on 
the question on physical activity during leisure hours. Activity was categorized into 
three groups; low (sedentary), middle (moderate activity) and high (regular exercise 
and training). Smoking was categorized in three groups; never, former and current 
smoker. Education was categorized into three groups; low (elementary school), middle 
(senior high school, technical and vocational school) and high (university). 
Hypertension was categorized as “yes” in subjects having systolic blood pressure ≥140 
and/or diastolic blood pressure ≥90 and/or on anti-hypertensive treatment, and as “no” 
in subjects having blood pressure <140/90 and no hypertension treatment. 
3.1.7 Sample description and genotyping  
All included subjects had complete data on FFQ as well as on potential confounders at 
baseline. The study was based on partly different samples. The first sample included all 
subjects participating in the follow-up study, thus having either NGT or prediabetes at 
baseline. Cases were subjects who had progressed regarding their glucose tolerance at 
follow-up; from NGT at baseline to either prediabetes (IGT or IFG or the combination 
of the two) or to type 2 diabetes at follow-up or from prediabetes at baseline to type 2 
diabetes at follow-up. Controls were all other subjects, i.e. those who did not display 
deterioration of glucose tolerance from baseline to follow-up. The second sample was a 
subgroup of the first sample and included only subjects with NGT at baseline. Cases in 
the second sample were subjects who progressed to either prediabetes or to type 2 
diabetes at follow-up, whereas controls were subjects displaying NGT at both baseline 
and follow-up. 
In a third sample, a subgroup of the first sample, data on TCF7L2 gene variants were 
available. DNA extraction and genotyping had previously been performed. Briefly five 
SNP were genotyped [108]. A selection of gene variants rs7903146 and rs4506565 was 
made for further association analysis. This sample comprised only men and cases were 
those who, from NGT or prediabetes at baseline, developed type 2 diabetes at follow-
up. Controls displayed NGT at both baseline and follow-up. 
 
3.2 ANIMALS AND CELL LINES 
All animal studies were performed in accordance with guidelines from the Swedish 
National Board for Laboratory Animals and approved by the Northern Stockholm or by 
the Northern Swedish Ethical Committee on Experimental Animal Care. For the 
transplant study (paper II) inbred Wistar-Furth rats were used. For in vitro experiments 
Sprague-Dawley rats (an outbred model), were used. All animals were obtained by 
Scanbur (Sollentuna, Sweden).  
The rat insulinoma cell line INS-1 (paper III and IV), characterised by Asfari M et al. 
1992 [109], was chosen as origin for cell model. This cell line has been used 
extensively to study the mechanisms involved in regulation of insulin secretion because 
of its responsiveness to glucose at levels found in vivo [110]. From the INS-1 a stable 
clone of INS-1r9 was established. INS-1r9 carries the reverse tetracycline/doxycycline-
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dependent transactivator [111] which has been described elsewhere [112, 113]. The 
plasmid used in the secondary stable transfection was constructed by subcloning the 
complementary DNA (cDNA) encoding the rat CD36 into the expression vector 
PUHD10-3 [111]. The procedures for stable transfection, clone selection and screening 
were previously described by Wang 1997 [112]. The CD36*10 clone was chosen for 
further experiments. 
 
3.2.1 Islet and cell line culture, and islet isolation 
Islets of Langerhans (paper II) were isolated by collagenase digestion in Hank’s 
balanced salt solution (HBSS) as previously described [114], followed by 
sedimentation. Islets were handpicked under stereomicroscope and transferred to petri 
dishes containing RPMI1640, 2 mmol/l glutamine, 10 % (v/v) fetal bovine serum 
(FBS), 100 U/ml benzylpenicillin, 0.1 mg/ml streptomycin and 11 mmol/l glucose and 
cultured free-floating overnight at 37°C in an atmosphere of 5% CO2 in air. For in vitro 
experiments islets from Sprague-Dawley rats were isolated and cultured overnight with 
different glucose concentrations as indicated by each experimental protocol. In long-
term culture (two and three weeks respectively) islets were cultured in 0.5 % BSA 
instead of fetal calf serum. Culture media were changed every 2-3 day. After culture, 
equal-sized islets were transferred to dishes with Krebs–Ringer bicarbonate (KRB) 
medium, 10 mmol/l Hepes, 0.2% BSA, and 3.3 mmol/l glucose, and pre-incubated for 
30 min at 37°C. They were then collected for electron microscopy, batch incubation, 
Western blot and measurements of ATP, ADP and DNA. 
Cells (paper III and IV) were cultured in RPMI 1640 with 11 mM glucose, 10 mM 
HEPES, 10 % heat inactivated FBS, 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 1 mM sodium pyruvate, 50 µM 2-mercaptoethanol. Further, INS-1r9 
media was supplemented with geneticin 150 mg/ml and INS-1 CD36 was additionally 
supplemented with 100 mg/ml hygromycin. Overexpression of CD36 was obtained by 
culturing cells with doxycycline (75–500 ng/ml). Cells were grown in monolayer, split 
weekly by trypsin and all experiments were performed between the passages of 60-100. 
 
3.2.2 Glucose-induced insulin secretion measurements  
Following culture and pre-incubation as described above, equal sized islets (paper II) 
were incubated in groups of three for 60 min at 37°C in KRB (3.3 or 16.7 mmol/l 
glucose). Each experimental condition consisted of three or four individual groups of 
three islets. The insulin accumulated in the KRB was measured as previously described 
[115]. Islet insulin contents were measured after acid-ethanol extraction [116] of islets 
retrieved from batch incubations. 
Cells (paper III and IV) were cultured for 48 h ±doxycycline (500 ng/ml) (in order to 
achieve overexpression of CD36). For long-term experiments cells were cultured 
±doxyxycline and ±palmitate or oleate (50 µmol/l) (paper III) or nLDL or oxLDL (20 
µg/ml or 50 µg/ml) (paper IV) for another 48 h. Prior to glucose-induced insulin 
secretion cells were cultured for 2-3 h in RPMI without glucose, with 20 mM HEPES 
and with 1% FBS. Cells were further pre-incubated for 30 min in Krebs-Ringer 
bicarbonate buffer (KRB) without glucose and, with 10 mmol/l HEPES and 0.2% BSA. 
Final incubations were made in same KRB but with the indicated glucose 
concentrations of 2.5 and 21.5 mM for 30 min. For acute experiments cells were 
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cultured for 48 h and then precultured and preincubated as previously mentioned and at 
final incubation palmitate (100 µmol/l or 50 µmol/l) or oleate (100 µmol/l) (paper III) 
or nLDL or oxLDL (20 µg/ml or 50 µg/ml) (paper IV) was added. Aliquots of secretion 
into media were secured. Acid ethanol was added to cells to extract cellular insulin 
contents. 
 
3.2.3 Transplant protocol 
One day after birth male rats (paper II) were made diabetic by an intra-peritoneal 
injection of 90 mg/kg streptozotocin (Sigma). Diabetes was confirmed by blood 
glucose >10.0 mmol/l at day three. Female syngenic rats i.e. immunologically 
compatible for transplantation, were used as donors. Islets of Langerhans were isolated 
from 16-20 weeks old rats as previously described and cultured overnight. The 
following day 50-150 islets were transplanted under the left kidney capsule as 
previously described [92, 117]. To minimize inter-donor variation islets isolated from 
two to three rats were mixed and divided into three equal portions; one third was 
transplanted to a non-diabetic rat (later vehicle-treated), one third to diabetic rats (later 
vehicle-treated) and one third to diabetic rats (later treated with tifenazoxide). The 
number of islets transplanted to each rat was purposely kept low enough not to reverse 
diabetes in the recipients. Following transplantation, rats were administered vehicle 
(non-diabetic and diabetic recipients) or tifenazoxide (3 mg/kg, diabetic recipients) 
once daily between 08.00 and 10.00 hours by gavage. The vehicle component consisted 
of glycerol 5 vol %, gelatine 0.5 %, 40 vol % and carboxy-methyl-cellulose 2 %, 55 vol 
%. Tifenazoxide was dissolved in 2 % NaOH. The treatment period lasted for 63 days. 
It was followed by 7 days of wash-out, i.e. the cessation of vehicle or tifenazoxide 
administration. The transplants were cut out of from the under renal capsule. At all 
times the animals had free access to water and a standard laboratory chow for rats 
(Scanbur, Stockholm, Sweden). Blood glucose levels were measured non-fasting once 
every week between 08.00 and 10.00 hours (i.e. just before medication) throughout the 
experimental period. 
 
3.2.4 Electron microscopy - ultrastructural morphometry 
Transplants (paper II) were excised from under renal capsule and fixed in ice cold 
mixture of 2.5% glutaraldehyde in 0.05 M phosphate buffer, pH 7.2, with an osmolarity 
of 390 mOsmol/kg. After dehydration transplants were embedded in an epoxy resin. 
Ultra-thin sections giving a silver interference colour were prepared on an 
ultramicrotone and picked up on form coated one-hole grids. The sections were stained 
with uranyl acetate and lead citrate. The electron microscopy was performed with a 
Hitachi H-700 with 75 kV acceleration tension. After fixation and embedding, eight 
transplants from each experimental group were prepared for electron microscopy. 
Twenty-two electron micrographs at a primary enlargement of 7200x were made from 
each transplant. The micrographs were distributed over the sections areas by systematic 
random sampling of beta-cell-rich areas. The negative film was scanned and analysed. 
In the stereological analysis, beta-cells were identified by their typical appearance of 
secretory granules. A total of 176 sections were analysed per treatment group. Totally 
528 electron micrographs sections were analysed including approximately 25.000 
mitochondria. Next a grid was applied to the image and parameters analysed. The 
methods to calculate the parameters are previously described [118, 119]. Insulin 
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granules were calculated and classified as mature or immature. Mature granules were 
classified by the appearance of a dense core and wide halo whereas the immature 
granules were classified by the appearance of pale core and narrow halo. Also for 
insulin granules volume density, number of granules and average volume were 
calculated in a similar fashion as for mitochondria. 
 
3.2.5 Subcellular fractionation and Western blots 
Cells (paper III) were grown ±doxycycline (500 ng/ml). Cells were washed, harvested 
and homogenized with a pestle motor followed by 10 passages through a syringe in 
homogenization buffer. Homogenate was centrifuged at 700 x g for 15 min. 
Supernatant was mixed with sucrose (250 mM) and Percoll (15 %). Further 
centrifugation was performed at 48 000 x g for 25 min. The plasma membrane (top 
fraction) and insulin granule (bottom fraction) were collected. Fractions were washed 
two times in homogenization buffer by 150 000 x g centrifugation for 30 min. Cytosol 
fraction was obtained by centrifugation of homogenate at 150 000 x g for 60 min [120]. 
Plasma membrane fraction was confirmed by western blot with a Na
+
 /K
+
 ATPase 
antibody. Secretory granules were confirmed by measurement of insulin (measured by 
RIA as previously described). 
 
After culture, islets (paper II) or cells (paper III and IV) were washed and protein 
concentration (for cells) was measured by DC protein assay (BIO-RAD). Samples were 
denatured in loading buffer at room temperature for 20 min or at 80°C for 10 min. 
Samples were analysed on 7.5-12% sodium dodecyl sulfate polyacrylamide 
electrophoresis gels (SDS-PAGE) run for 1 h at 150 V and were then transferred to 
nitrocellulose membrane for 1 h at 250 mA. Membranes were blocked for 2 h at room 
temperature with 5% (w/v) fat-free milk, 0.1% Tween 20 (Sigma) in Tris-buffered 
saline, pH 7.6 for 2 h at room temperature. Membranes were then incubated overnight 
at 4° C with primary antibody (see table 2). Membranes were washed in Tris-buffer for 
1 h and then incubated in 2.5 % fat-free milk in 0.1% Tween 20 in Tris-buffered saline 
with secondary antibody. Secondary antibody incubations employed a HRP-linked anti-
mouse or goat-anti rabbit (Pierce Biotechnology) for 1 h at room temperature. Bands 
Table 2. Western blot antibodies 
Primary 
antibody 
 
Type 
 
Species 
 
Dilution 
 
Origin 
Total 
OXPHOS 
Cocktail 
Monoclonal Mouse  1:5000 MitoSciences USA 
OPA-1 Monoclonal Mouse 1:1000 BD Biosciences Transduction 
Laboratories, Sweden 
CD36 Polyclonal Rabbit 1:500 Santa Cruz Biotechnology, USA 
Na
+
/K
+ 
ATPase 
Monoclonal Mouse 1:2000 Millipore, USA 
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were visualized by chemiluminescence kit (Pierce Biotechnology), exposed to film 
(Amersham Biosciences) and documented with a flat-bed scanner and quantitation 
software (Kodak 1D). 
 
3.2.6 Real-time reverse transcription PCR 
We used PCR to quantify the relative amount of mtDNA (paper II) present per nDNA. 
DNA was extracted by DNeasy Blood & Tissue kit (Qiagen). Mitochondrial relative 
DNA copy number was determined by calculation of the mtDNA/nDNA to the control 
ratio (i.e. 11 mmol/l glucose). mtDNA-encoded NADH dehydrogenase 2 gene (ND-2) 
was used as a marker for total mtDNA and 18S ribosomal DNA for nDNA. 
Cells (paper III) were treated as for long-term insulin secretion experiments. After that, 
cell total RNA, isolated using an RNeasy mini kit (Qiagen), was reverse-transcribed 
using random hexamer primers and SuperScript II (Invitrogen) according to the 
manufacturer's instructions. The real-time RT-PCR was monitored and analysed by the 
Sequence Detection System (Applied Biosystems). All genes were normalized to18S 
and beta-actin. 
 
3.2.7 ATP, ADP and DNA measurements 
ATP (paper II) was determined using a bioluminescence kit (Roche Diagnostics). ADP 
was measured after enzymatic removal of ATP, as described previously [121]. For 
DNA, islets (paper II) were washed twice with cold PBS and 1 µl PBS/islet was added 
followed by sonication. Fluorescent DNA Quantitation Kit (Bio-Rad) was used 
according to manufacturer’s instructions. 
 
3.2.8 Respiring mitochondria and oxygen consumption 
A cell suspension was prepared from islets (paper II) by trypsin digestion as described 
previously [122]. Cell suspension were directly plated on polylysine-coated cover 
glasses in Petri dishes and cultured for 48 hours in RPMI 1640 supplemented with 5.5 
or 27 mmol/l glucose ± diazoxide (325 µmol/l). After culture cells preincubated in 3.3 
mmol/l glucose for 30 min at 37°C and 70 nmol/l Red CMXRos, MitoTracker Red 
(MTR) (Molecular probes) was added for 10 min and then rinsed. MTR is a cell-
permeable selective dye, which passively diffuses across plasma membranes and 
accumulates in active mitochondria. The dye covalently binds free sulfhydryls and does 
not fluorescence until it enter an actively respiring cell. To reduce potential artefacts 
and mitochondrial toxicity from overloading, the dye concentration was held as low as 
possible (70 nmol/l). Live cell images were collected using a Leica SP2 spectral laser 
scanning confocal microscopy system equipped with a 250 mW argon/krypton laser 
(Omnichrome Inc.). The technique for measurement of MTR labelled beta-cells has 
been described in detail [123]. 
 
The oxygen consumption (paper II) was measured by Clark-type polarographic oxygen 
sensors and high-resolution respirometry (Oxygraph-2k, OROBOROS). Samples of 
400 islets (paper II) in cell culture medium were added to a chamber recording oxygen 
uptake at basal respiration during 20 min of stable oxygen consumption. Consumption 
rates were calculated as the negative time derivate followed by the addition of 2 µg/ml 
oligomycin of the oxygen concentration present in the chamber (pmol/s/400 islets). 
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3.2.9 LDL isolation, preparation and labelling 
LDL (paper IV) (density = 1.019 – 1.063 g/ml) was isolated by ultracentrifugation from 
pooled plasma of healthy donors obtained from Blood Central of Karolinska University 
Hospital, Stockholm Sweden, as described [124]. 2 mmol/l Benzamidine, 0.5 mmol/l 
PMSF and 0.1 U/ml Aprotinin (all from Sigma-Aldrich), were added immediately after 
the plasma was prepared. After isolation, LDL was dialyzed extensively against PBS. 1 
mmol/l EDTA (Sigma-Aldrich) was added to an aliquot of LDL to generate unmodified 
LDL. Oxidized LDL was obtained by incubating 1 ml of LDL (1 mg/ml) protein 
content, determined by Bradford assay, (BIO-RAD) in the presence of 20 μmol/l 
CuSO4 (Sigma-Aldrich) for 18 h at 37°C. The oxidation of LDL leads to the formation 
of lipid peroxidation products, i.e. malondialdehyd (MDA), that are reactive to 
thiobarbituric acid (TBARS). The extent of oxidation was evaluated as described [125]. 
Lipoprotein preparations were sterilized by passage through
 
a 0.22 µm filter. 
LDL was labelled by fluorescein isothiocyanate (FITC) using a modification of a 
previously described method [126]. Briefly, LDL (1.5-2 mg/ml) was dialyzed overnight 
against 500 mmol/l NaHC03 pH 9.5. Next, 100 µg of FITC (Sigma-Aldrich), dissolved 
in DMSO (1 mg/ml), was added for each mg of LDL and incubated at room 
temperature for 2 h. After incubation conjugates were separated from the free 
fluorochrome by filtration on a PD 10 column using PBS for elution. FITC 
concentration in LDL preparations was measured by absorption spectroscopy against 
FITC standard at 495 nm. Protein concentration was determined by Bradford assay 
(BIO-RAD). Radiolabeled LDL was obtained with the incorporation of [1,2-
3
H] 
cholesteryl oleate as previously described [127]. In brief, 1 mCi of [1,2-
3
H] cholesteryl 
oleate was dried under N
2
 and then re-dissolved in 100 mL of dimethyl sulfoxide. LDL 
(20 mg protein/mCi) was then added to the solution and allowed to incubate for 2 
hours. At the end of the incubation period, free excess of [1,2-
3
H] cholesteryl oleate 
was removed by PD10 gel-filtration (GE Healthcare). 
 
3.2.10 Fatty acid uptake and efflux 
Cells (paper III) were cultured ± doxycycline (500 ng/ml). For uptake experiments cells 
were counted in Bürker chamber and equal amount of cells were transferred to tubes 
and centrifuged for 2 min 1000 rpm. Cells were re-suspended in ice-cold KRB with 11 
mmol/l glucose and 2.1 µCi (6 µmol/l) 
14
C-oleate (GE Healthcare) and transferred in 
triplicates to micro-centrifugation tubes which were prepared with a bottom layer of 6 
mol/l urea over layered by a 10:3 mixture of dibutyl-dinonylphtalate [128]. Uptake was 
stopped by centrifugation at 8000 rpm for 15 s. The urea layer containing the cells was 
cut off and put into scintillation vials. Scintillation liquid was added and samples were 
transferred to a gamma counter (Packard). 
In some uptake experiments an irreversible inhibitor of CD36 Sulfo-N-Succinimidyl-
oleate (SSO) was used (a kind gift from Dr N.A. Abumrad Washington University 
School of Medicine). SSO was prepared in 1 M stock solution in DMSO. Cells were 
preincubated for 25 min in 37°C in KRB without glucose and with or without 0.5 
mmol/l SSO. DMSO concentration was kept below 0.05% and was added to control 
experiments. Cells were washed, and further treated as above. For efflux experiments 
cells were washed and then incubated with KRB and 
14
C-oleate (same concentration as 
for uptake experiments) for 4 min in room temperature. Cells were then centrifuged and 
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re-suspended in ice-cold 2 % BSA-KRB and efflux stopped at different time points. 
Radioactivity in the separated cells was processed as above. Aliquots from efflux media 
were saved for thin layer chromatography (TLC). 
 
3.2.11 Uptake and efflux of FITC / 3H-cholesterol LDL 
3.2.11.1 FITC-LDL 
Cells (paper IV) were cultured for 36 h in 10% FBS ±doxycyline (75 or 500 ng/ml). 
They were then further cultured in media containing 1% FBS for 12 h ±doxycycline. 
Fresh culture media with 1 % FBS with or without LDLs (20 µg/ml) were added. After 
30 min and onward time-points cells were washed twice with ice cold PBS. Cells were 
then flushed off by vigorous pipetting, transferred to tubes and centrifuged at 1000 rpm 
for 2 min at 4°C. Supernatants were discarded and cells re-suspended in 4 % 
formaldehyde (PAF). The uptake of FITC-labeled nLDL and oxLDL was analysed on a 
CyAnTM ADP flow cytometer (Dako). For each experiment 10,000 events were 
acquired. The fluorescence of cells without added lipoproteins or FITC was used as 
control. Uptake of FITC nLDL and oxLDL was also performed in low (2.5 mmol/l) or 
high (21.5 mmol/l) glucose. In some experiments the uptake of LDLs was also 
performed with INSr9 cells (which only harbour the doxycycline gene). 
For efflux experiments uptake media were removed and efflux media with HDL as 
acceptor with or without doxycyline (500 ng/ml) was added to cells. They were then 
cultured to allow efflux for 4 h. From results of preliminary experiments with 10-250 
µg/ml of HDL a concentration of 50 µg/ml was chosen for further experiments. Efflux 
was stopped and collection of cells was performed as described above. 
 
3.2.11.2 3H-cholesterol LDL  
CD36 overexpression (paper IV) was induced with doxycyline (500 ng/ml) as for FITC 
experiments. The uptake of 
3
H-labelled LDLs was assessed after culture with 
3
H-
cholesterol-nLDL or 
3
H-cholesterol-oxLDL (20 µg/ml) for 24 h in 1% FBS. Cells were 
then washed with PBS and lysed in acid ethanol. Aliquots were later counted in a 
scintillation counter. 
Efflux of 
3
H with HDL as acceptor was measured at different time points after uptake 
of 
3
H. Media were then secured and cells were lysed in acid ethanol (to measure 
remaining radioactivity). 
 
3.2.12 Thin layer chromatography 
After incubation ± doxycycline (500 ng/ml) for 48 h, and then further incubation with 
14
C-Oleic or 
14
C-palmitic acid (1 µCi, 18.9 and 16.7 µmol/l respectively, GE 
Healthcare) for 30 min, 4 or 48 h cells (paper III) were washed in PBS, trypsinized and 
washed again. To the cell pellet chloroform/methanol (2:1) was added together with 
3
H-triolein (0.05 µCi, internal standard, Perkin Elmer Life and Analytical Sciences). 
This was followed by 30 min of incubation with periodic vortexing at room 
temperature. After centrifugation (6000 rpm for 2 min), the phases were separated by 
adding NaCl (0.9%) followed by centrifugation (2000 rpm for 2 min). The upper phase 
was removed and the lower organic phase was dried under N2-gas. The dried lipids 
were solubilised in chloroform/ethanol (9:1) and applied to a Silica gel TLC plate 
(Merck). TLC Mix 32 (Larodan Fine Chemicals) was used as a positive control. 
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Petrolium ether/Ether/Acetic acid (79:20:1) was used as mobile phase. The lipids were 
visualized by spraying with phosphomolybdic acid. Spots representing lipids were cut 
out, mixed with scintillation cocktail and counted for 
3
H and 
14
C radioactivity. Aliquots 
from efflux experiments were performed specifically for fractionation of oleate. The 
procedure was basically the same as for cells with the exception that unlabelled oleate 
was added to each sample before the TLC procedure. 
 
3.2.13 Oil Red O and triglyceride measurement 
Cells (paper III and IV) were cultured in the indicated concentration of doxycycline, 
palmitate, nLDL and oxLDL for 48h. Cells were fixed in 4 % PAF, rinsed and stained 
with oil red O and counterstained with hematoxylin. 
Cellular triglycerides (paper III) were extracted according to Folch et al. [129] and 
measured using the Triglyceride (GPO-TRINDER) kit (Sigma). 
 
3.2.14 Fatty acid oxidation and CPT1 activity 
Cells (paper III) were cultured ±doxycycline (500 ng/ml) for 48 h and treated as for 
insulin secretion experiments. Cells were then incubated in 2.5 and 21.5 mmol/l 
glucose KRB in the presence of 0.084 μCi (14 μmol/l) of [1-14C]-oleate (GE 
Healthcare). Incubations were carried out in a shaking water bath at 37 °C for 2 h in 1-
ml glass tubes inside 20-ml scintillation vials. Incubation was stopped by injection of 
0.1 ml of 0.1 mol/l HCl and hyamine was added to scintillation vials. The sealed 
scintillation vials were left overnight, at room temperature, to absorb 
14
CO2 into the 
hyamine. Samples were put in counter and data were expressed as pmol [1-
14
C]-
oleate/2 h/1x10
6
 cells. 
For CPT1 activity, cells (paper III) were induced with doxycycline (500 ng/ml) for 48 
h. During the last 24 h of this period the glucose concentration was changed from 11 to 
either 5.5 or 27 mmol/l glucose. CPT1 activity was determined by a radiometric 
method as described in Morillas et al. [130]. 
 
3.2.15 Oxidative stress 
For measurement of oxidative stress cells (paper III) were cultured for 48 h 
±doxycycline (500 ng/ml). Cells were then washed and re-suspended in PBS, and 
loaded with 5 μmol/l CM-H2DCFH-DA (Molecular Probes) for 20 min at 37 °C. 
Following loading, cells were exposed to 40 or 400 μmol/l of H2O2. The production of 
ROS was assessed by measuring the fluorescent signal evoked by the deacetylated 
product (DCF) in the setting of a 488 nm argon laser and 550 ±20 band-pass filters. 
 
3.2.16 Mitochondrial mass 
Mitochondrial mass was assessed by fluorescence of the Mito Tracker Green 
(Molecular Probes M7514). This probe is taken up into mitochondria, producing a 
fluorescence signal which is reportedly not affected by the prevailing mitochondrial 
membrane potential, thereby providing a measure of mitochondrial mass. After culture, 
cells (paper III) were collected, washed and re-suspended in PBS. Cells were loaded 
with 0, 20, and 50 nmol/l Mito Tracker Green for 30 min at 37 ˚C. After loading, dead 
cells and fragments were gated-out by forward and side scatters. The mitochondrial 
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mass was assessed by measuring the fluorescent signal in the setting of a 488 nm argon 
laser and 550 ± 20 band-pass filters. 
 
3.2.17 Viability assays 
For the different tests of viability, cells (paper IV) were cultured in for 48 h 
±doxycycline (500 ng/ml) and then further incubated for 48 h ±doxycycline and/or with 
20, 50 or 100 µg/ml nLDL or oxLDL. For the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay [131] media were removed and fresh media 
with MTT solution 0.5 mg/ml (Sigma-Aldrich) were added to the wells. The plates 
were incubated for 6 h at 37°C in an atmosphere of 95 % O2 and 5 % CO2. One half of 
the volume of the media was removed and 2-propanol, supplemented with HCl (3.3 
ml/l), was added to solubilize the MTT formazan. The plates were then placed on a 
mechanical shaker for 1 h at room temperature to complete solubilisation. Absorbance 
was measured at 570 nm using Multiskan Ascent microplate photometer (Thermo 
Scientific). 
Cytotoxicity was also evaluated by the release of lactate dehydogenase (LDH) into 
culture media using a LDH assay kit (Cayman Chemicals). Culture plates were 
centrifuged for 10 min at 200 x g. Culture media was removed and cells were lysed for 
30 min and further analysed according to manufacturer’s protocol. 
For apoptosis measurements, cells (paper III) were exposed to test agents, oleate (100 
µmol/l) and palmitate (50 µmol/l) ±doxycycline (500 ng/ml) in 11 mmol/l glucose and 
10 % FCS for 48 h. Camptothecin (positive control) was added only during the last 12 
h. Cells were detached by treating with 0.05 % EDTA in PBS and collected by 
centrifugation. Apoptotic and necrotic cells were dual stained with Annexin V and 
propidium iodide using a Vybrant® Apoptosis Assay Kit #2 (Molecular Probes). Flow 
cytometric analysis was performed using a 15 mW argon laser (488 nm), 550 nm 
diachronic long-pass filter and 550 ± 20 nm band-pass filter detecting Annexin V and 
675 ± 15 nm band-pass filter detecting propidium iodide. The percentage of apoptosis 
and necrosis was calculated from 3 separate experiments. 
Apoptosis was also measured in paper IV with the use of a cell death detection ELISA 
kit (Roche) according to manufactures instructions. 
DNA fragmentation (paper III) was assessed by the Quick Apoptosis DNA Ladder 
Detection Kit (LabForce/MBL) following the manufacturer's protocol. 
 
3.2.18 Confocal microscopy 
After uptake of FITC-labelled LDLs for 24 h cells (paper IV) were transferred to slides 
by using Shandon Cytospin 2 at 500 rpm for 5 min. Nuclei were stained by DAPI 
(1:250000) (Sigma-Aldrich) in PBS for 10 min. Slides were then washed twice in PBS 
and mounted. Cell fluorescence was analysed with a Leica TCS SP5 (Leica 
Microsystems) microscope equipped with filters for the detection of DAPI and FITC. 
Images were acquired at x63 magnification using an immersion oil objective and the 
Leica Application Suite Advanced Fluorescence software. 
Cells (paper III) were grown ±doxycycline 500 ng/ml. Cells were fixed in 4 % (PAF) 
phosphate buffer and then permeabilised for 1 h in PBS containing 0.1% saponin and 
0.5% BSA. The cells were incubated with CD36 antibody (Cascade Bioscience, mouse 
monoclonal IgA, clone 63, 1:500). They were then exposed to insulin antibody after 
which FITC- or Rhodamine-conjugated secondary antibodies were applied. Samples 
 26 
 
were analysed using a Zeiss laser confocal microscope. Images were taken with a 60× 
objective. 
 
3.3 STATISTICAL ANALYSIS 
Paper I: Data are given as mean with 95% confidence interval (CI) or numbers 
(proportions). Comparisons of continuous variables were performed by unpaired t-test 
or one-way ANOVA for independent groups, by paired t-test for dependent groups and 
by chi-square test for categorical variables. Odds ratios (OR), together with 95% CI 
were calculated by multiple logistic regression analysis. Intake of wholegrain and fiber 
was categorized into tertiles according to the distribution among all included subjects or 
used as continuous variables, reported as a decrease by 30 g/day (wholegrain) or 10 
g/day (fiber). Since no statistical interaction was found between sex and intake of 
wholegrain or fiber, analyses are reported not only separately, but also for women and 
men combined. When categories of wholegrain or fiber were used in the logistic 
regression analyses, tests for linear trend were conducted by assigning median values in 
tertiles of wholegrain or fiber as a continuous variable. In analyses of genotype 
association both additive and dominant models were used. In the evaluation of the 
interaction between genotype and intake of fiber or wholegrain, multiplicative product 
terms were included in the logistic regression models. Differences between models 
with and without product term were evaluated by log-likelihood ratio test. Linear 
regression analysis was used to evaluate associations between intake of fiber or 
wholegrain and baseline values of HOMA-IR, HOMA- β, insulin-response(2h-0h) or 
proinsulin. In these analyses HOMA-IR, HOMA- β, insulin-response(2h-0h) and 
proinsulin were log transformed to improve skewness. P-values <0.05 were considered 
significant and we did not adjust p-values for multiple testing. The analyses were 
performed using the SAS Statistical Program version 9.2 (SAS Institute, Cary, NC, 
USA). 
Paper II: Data in tables and figures are expressed as means ± SEM. For multiple 
comparisons, one-way ANOVA was performed. When normality test failed then 
Kruskal-Wallis ANOVA on ranks followed by Student-Newman-Keuls post-hoc test 
was performed. A p value of less than 0.05 was considered significant. 
Paper III and IV: Results are expressed as mean ± SEM. Significant differences were 
tested using Student’s paired t test (two-sided). A P value < 0.05 was considered 
significant. 
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4 RESULTS 
 
4.1 PAPER I  
At follow-up 12.8% of subjects had deteriorated in glucose tolerance, men more than 
women.  
Results are focused on wholegrain since wholegrain generally revealed stronger 
associations than total fiber. A low intake of wholegrain was associated with an 
increased risk for deterioration in glucose tolerance (i.e. progress from NGT to 
prediabetes or type 2 diabetes, or from prediabetes to type 2 diabetes). 
 
The subjects who at baseline had NGT and at follow-up had progressed to prediabetes 
showed the strongest association with intake of wholegrain. Analysing men and women 
separately, the association was stronger in men compared to women. However no 
interaction between sex and wholegrain intake could be documented. 
 
Linear regression analysis revealed an inverse association between HOMA-IR at 
baseline and intake of wholegrain at baseline for all subjects. An inverse association 
was also found for intake of wholegrain at baseline and insulin response(2h-0h) for all 
subjects. 
 
Subjects who had deterioration of glucose tolerance i.e. progressed to either prediabetes 
or type 2 diabetes were categorized into tertiles of their baseline values of HOMA-IR, 
HOMA-beta and insulin response(2h-0h). The majority of cases in the highest tertile of 
HOMA-IR were also found among those in the highest tertiles of HOMA-beta and of 
insulin response(2h-0h). 
 
Linear regression analysis revealed an inverse association between proinsulin and 
intake of wholegrain among all men. Proinsulin levels for subjects who later 
deteriorated in glucose tolerance increased significantly by increasing tertiles of 
HOMA-beta. 
 
Individual intake of wholegrain at baseline was similar to intake at follow-up. 
 
Evaluations of associations between intake of wholegrain and fiber and TCF7L2 
rs7903146 and rs4506565 were done in a subset of men. A significant association was 
found between baseline intake of wholegrain and development of type 2 diabetes at 
follow-up. When stratified on genotypes, no associations were found in subjects 
carrying the T-allele (risk allele for both SNPs), either in heterozygotic or homozygotic 
carriers, between decreased baseline intake of wholegrain at baseline and development 
of type 2 diabetes after adjustment for all confounders. In non-risk allele carriers i.e. 
CC (rs7903146) and AA (rs4506565) an increased risk to develop type 2 diabetes was 
found with decreasing intake of wholegrain. Assuming an additive model, interaction 
terms, genotype × intake of wholegrain, included in the regression model, were 
significant for both SNPs for wholegrain. Since individuals with heterozygous 
genotype conferred a significant risk of diabetes compared to non-risk allele carriers a 
dominant model of inheritance was also evaluated, and similar results were obtained. 
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4.2 PAPER II 
4.2.1 In vivo results 
Transplantation moderately but swiftly decreased blood glucose in the diabetic-vehicle 
treated rats, (presumably because of the added beta cell mass). Such a rapid decline was 
not apparent in tifenazoxide-treated rats, probably because of the blocking effect of this 
compound on insulin secretion. All in all, moderate hyperglycaemia prevailed. Body 
weight increased less in the vehicle-treated diabetic rats than in non-diabetic recipients. 
Body weight did not increase appreciably in tifenazoxide-treated diabetic rats. 
 
The outer surface area of mitochondria per unit beta cell volume (SVM) was decreased 
by 12 % by the diabetic state. Most importantly the number of mitochondria per unit 
beta cell volume (NVM) was decreased (by 31 %) in vehicle-treated diabetic rats 
compared to non-diabetic rats. 
 
Secondary parameters showed that the diabetic state led to larger mitochondria as 
demonstrated by an increase in average mitochondrial volume by 68 % (VVM/NVM), and 
average mitochondrial outer surface area by 38 % (SVM/NVM). Conversely, the 
mitochondrial outer surface area per unit mitochondrial volume (SVM/VVM) was 16 % 
smaller in diabetic vs. non-diabetic rats. This indicates that there was a change in shape 
from elongated to more round mitochondria in diabetic vs. non-diabetic vehicle-treated 
animals. We observed mitochondria of at least 2-3 fold increased size and with reduced 
density in many sections of grafts in vehicle-treated diabetic animals. The variation in 
average mitochondrial volume and outer surface area was larger in grafts from vehicle-
treated diabetic vs. non-diabetic treated animals. Treatment with tifenazoxide partially 
corrects effects by the diabetic milieu. Previous tifenazoxide-treatment of the diabetic 
rats partly but significantly normalized the diabetes-induced differences in average 
mitochondrial volume and average mitochondrial outer surface area, p < 0.05. 
Tifenazoxide also reduced the variability of mitochondrial size by eliminating mega-
mitochondria. 
 
Insulin granules were quantified according to volume of granules per unit beta cell 
volume VVM, number of granules per unit beta cell volume NVM and average volume 
VVM/NVM. All parameters were decreased in beta cells from grafts in diabetic animals 
for the mature granules. 
 
Qualitative ultra-structural findings from vehicle treated non-diabetic animals showed 
that mitochondrial profiles were round or elongated and the mitochondria had matrix of 
moderate density with distinct cristae in the internal membrane. Compared to vehicle-
treated diabetic animals which had low density and disrupted cristae with irregular 
pattern. Observations of fusion or fission of mitochondria were also present in the 
vehicle-treated diabetic animals. Tifenazoxide-treatment of the diabetic rats resulted in 
a beta cell morphology that seemed of that in transplants to non-diabetic recipients. 
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4.2.2 In vitro results 
Long-term in vitro culture in high glucose reproduced quantitative changes in 
mitochondrial morphology obtained in vivo. Abnormal morphometry associates with 
mitochondrial dysfunction. Glucose-stimulated insulin-secretion was decreased after 
long term culture in high glucose. 
 
Long-term culture in high glucose also reduced constituents of mitochondrial 
complexes I-IV and OPA1 and reduced the ATP and ADP levels. Basal oxygen 
consumption was higher in islets cultured in 11 mmol/l glucose compared to islets 
cultured in 27 mmol/l. Basal oxygen consumption was also more reduced after addition 
of oligomycin (an inhibitor of ATP synthase activity) in 11 mmol/l compared to 27 
mmol/l glucose. Likewise, was a measurement of active respiring mitochondria 
(measured by MTR) higher for the islets cultured in 11 mmol/l glucose compared to 27 
mmol/l glucose. 
 
4.3 PAPER III 
CD36 protein was found in the plasma membrane in a doxycycline dose dependent 
manner (shown by immunofluorescence and western blot on subcellular fractions). 
 
Cells with higher levels of CD36 protein had increased uptake of fatty acids but also 
increased efflux of fatty acids (demonstrated by efflux and TLC). Visual inspection 
(oil-red O) suggested an increased accumulation of lipids with increasing CD36 protein 
levels. Total cellular triglyceride content revealed a 20±5% increased accumulation 
with increased levels of CD36 protein. Yet the incorporations of isotope-labelled fatty 
acids were similar regardless of the CD36 protein levels. 
 
Fatty acids acutely potentiated the glucose-induced insulin secretion however this effect 
was abolished in cells with increased protein levels of CD36. After 48 h culture with 
fatty acids glucose-induced insulin secretion was reduced in cells with higher levels of 
CD36 protein. Fatty acid oxidation was inhibited by high glucose. This inhibition by 
glucose was moderately supressed in cells with increased levels of CD36 protein. The 
inhibiting effect of high glucose on CPT1 enzyme activity was also repressed in cells 
with increased levels of CD36 protein. 
 
Increased CD36 protein did not change the UCP-2 mRNA nor did it decrease the 
GPR40 mRNA. Increased CD36 protein did not induce apoptosis measured by DNA-
laddering and Annexin V nor was increased ROS formation seen. 
 
4.4 PAPER IV 
An increased level of CD36 protein dose-dependently enhanced the cellular uptake of 
FITC-labelled oxLDL while no enhanced uptake was seen for FITC-labelled nLDL. 
Cells without increased levels of CD36 also displayed increased uptake of oxLDL 
compared to nLDL however not to the same degree as the cells with increased CD36 
protein. Accumulation of FITC-labelled LDLs were visualised by confocal microscopy 
and an increased accumulation was seen for FITC-oxLDL cultured cells and especially 
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in cells with increased levels of CD36. However no accumulation of lipids could be 
detected by oil-Red O. 
 
Increased uptake of oxLDL in cells with overexpression of CD36 did not induce 
additional toxicity tested by apoptosis, LDH release and MTT. 
 
Culture for 48 h with oxLDL decreased glucose-induced insulin secretion. The 
decrease was similar regardless of levels of CD36 protein. OxLDL also reduced 
cellular insulin contents irrespective of levels of CD36 protein. 
 
3
H-cholesterol-oleate labelled oxLDL were taken up more than 
3
H-cholesterol-oleate 
labelled nLDL. But compared to FITC-labelled oxLDL there was no effect of increased 
levels of CD36 protein. 
Labelling cells for 24 h with 
3
H-cholesterol-oleate labelled LDLs and then performing 
efflux experiment showed that the LDLs are quickly effluxed from cells independently 
of CD36 protein levels. Increased HDL concentrations (work as acceptor) increased 
efflux of LDLs dose-dependently. However for FITC-labelled LDLs there was no 
increased efflux with increasing HDL concentrations. Also FITC-labelled oxLDL was 
retained in cells with increased levels of CD36 protein more than the 
3
H-cholesterol-
oleate labelled oxLDL. 
OxLDL up-regulated CD36 after 48 h culture. Also culture with nLDL increased CD36 
protein. 
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5 DISCUSSION 
 
5.1 PAPER I 
Because OGTT was performed both at baseline and follow-up we were able to identify 
subjects with prediabetes, i.e. IGT and/or IFG, and analyse them separately from type 2 
diabetes subjects. The clinical relevance of studying prediabetes has received more 
attention in the last years. A study from the US suggest that approximately 35% of US 
adults (over the age of 20 years) and 50% (over the age of 65 years) had prediabetes 
defined by fasting plasma glucose or HbA1c concentrations [132]. IGT is projected to 
increase according to International Diabetes Federation, furthermore American 
Diabetes Association expert panel estimates that 70% of individuals with prediabetes 
will eventually develop diabetes [132]. In our SDPP study, about 30-40% of 
individuals with prediabetes developed type 2 diabetes within 8-10 years [133]. 
 
In this prospective population-based cohort study we show a negative association 
between intake of dietary wholegrain (and to a lesser extent dietary fiber) and the 
development of prediabetes, i.e. IGT and/or IFG. 
 
We found only one population-based prospective study outside the US that has 
evaluated the influence of fiber and wholegrain on the development of type 2 diabetes: 
the Finnish study by Montonen et al. [82]. In the Montonen study wholegrain 
consumption was associated with reduced risk of type 2 diabetes. In the Finnish study, 
the participants were retrieved from health care examinations and the outcome (type 2 
diabetes) was assessed from the medical certificates needed for reimbursement of drug 
costs. Individuals with type 2 diabetes treated only with diet and changes in life-style 
were thus not identified. Furthermore, the Finnish study did not have the necessary data 
to adjust for FHD and physical exercise, both which are possible confounders. The 
Finnish study was rather small with 4316 participants; however an advantage was that 
they studied both men and women. Several US studies have shown inverse associations 
of wholegrain intake and risk of type 2 diabetes [134]. Compared to US studies [78, 
135] the intake of wholegrain was much higher in Montonen study [82]. It is known 
that the intake of wholegrain is much higher in Scandinavian countries, yet only 16-
35% of the population meet the recommendation of 75 g/day per 10 MJ [136]. 
 
A recent meta-analysis showed that wholegrain and dietary fiber intake was inversely 
associated with the risk for type 2 diabetes [134]. In our study, a negative association of 
wholegrain intake was found for type 2 diabetes when adjusted for age and sex: 
however it was not significant after full adjustment for confounders. This could 
probably be explained by the low number of individuals in the type 2 diabetes group. 
 
Although there was no significant difference between sexes (as tested by interaction 
term) the adverse association of low intake of wholegrain and fiber was stronger in 
men. One reason may be that our FFQ was validated in a group of middle aged men 
[106] but not in women. Hence, we cannot rule out the possibility that the questionnaire 
(which was the same for men and women) reflected somewhat less the actual intake in 
women than in men. Another important difference is the higher incidence of 
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deteriorating glucose tolerance in men vs. women in our study, which is in accordance 
with other studies [137]. Also the time to follow-up for women was somewhat shorter 
than for men. In any case our findings are in line with the difference by gender for the 
risk of type 2 diabetes in [82, 134]. 
 
To investigate the mechanisms behind the effect of wholegrain we tested associations 
of wholegrain intake with measurements of insulin resistance and beta cell function. 
We found an inverse association; low intake of wholegrain and fiber corresponded to 
increased insulin resistance. This finding is in line with cross-sectional studies [76, 138] 
and suggests that insulin sensitivity play a role in the protective effects. 
 
Elevated proinsulin levels are a feature of abnormal beta-cell function in type 2 
diabetes. Linear regression analysis revealed a negative association between proinsulin 
and intake of wholegrain among all men. In subjects deteriorating in glucose tolerance, 
the level of proinsulin was significantly increased in higher vs. lower tertiles of 
HOMA-beta at baseline. However, the proinsulin/insulin ratios remained unchanged. 
Thus, our data probably reflect the increased demands on beta-cell secretion that are 
induced by insulin resistance. 
 
Associations were stronger with wholegrain than with total fiber intake. This is in line 
with other studies, [134]. We therefore presume that fiber content per se does not 
altogether explain the favourable association to wholegrain intake. Many theories on 
mechanisms of wholegrain antidiabetic effects have been presented; they include 
increased mineral, vitamin and antioxidant content, beneficial effects of insoluble fiber 
through fermentation and formation of short chain fatty acids, gastric transit 
time/emptying, intestinal transit time and more [139]. The elucidations of which 
primary effects that are operative await further studies. 
 
We confirm effect modifications by polymorphisms of the TCF7L2 gene that were 
reported previously [85]. Our data show that the protective effect of wholegrain intake 
on the risk of developing type 2 diabetes was undetectable in subjects carrying the 
TCF7L2 rs7903146 T-allele. This finding is in line with a previous report [85] but is in 
disagreement with a meta-analysis [56], which did not find an influence of the TCF7L2 
rs 4506565 genotype. However, the meta-analysis did not test for association with type 
2 diabetes as in [85] but for an association with fasting glucose or fasting insulin 
measured in subjects without diabetes. It has been suggested that the diabetogenic 
variant of the TCF7L2 gene decreases GLP-1 expression and actions [140]. Since GLP-
1 is known to slow gastric emptying we speculate (in agreement with) [85] that loss of 
this effect in carriers of diabetogenic risk alleles could cancel out a similar effect 
exerted by wholegrain. Considering the fairly low number of subjects in our study for 
these analyses, confirmatory studies are needed. 
 
For the results based on our entire study population we acknowledge that it was rather 
small (5477 subjects) compared to the US prospective studies [134]. However our 
study was population-based and included both men and women. Several of the 
prospective studies from US [134] included health professionals who could be 
considered a heterogeneous group; hence generalizability from these studies may be a 
concern. 
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Strength of this study was that misclassification of type 2 diabetes and prediabetes was 
probably low since OGTT was performed in all participants thus providing us with 
direct measurements of glucose and insulin concentrations from which we could 
calculate HOMA for insulin resistance and beta cell function. 
A further positive feature was the possibility to check for changes in intake of 
wholegrain and fibers between baseline and follow-up. Since the intake was similar it is 
less likely that changes over time influence the results. 
The calculated mean intake of fiber among men corresponded well with both the FFQ-
validation study [106], and the most recent national food data survey results in Sweden 
by Becker and Pearson Riksmaten 1997-98 [74]. Women had higher total intake of 
fiber compared to men which also corresponds well with data from national food data 
survey [74]. These similarities strengthen the validity of our estimations of total fiber 
intake. However, the FFQ did not allow us to calculate total energy intake. This is a 
limitation of our study. 
 
In conclusion, low wholegrain intake associates with increased risk of deteriorating 
glucose tolerance especially progression from NGT to prediabetes. The adverse 
associations are primarily seen in men and linked to insulin resistance. Furthermore, we 
add evidence for effect modification by polymorphisms of the TCF7L2 gene. 
 
5.2 PAPER II 
Chronic moderate hyperglycaemia induces fewer, larger, swollen and more variably 
sized mitochondria, demonstrated by morphological abnormalities found in islet 
transplants from in vivo experiments. It seems important that these morphological 
changes could be reproduced by long term hyperglycaemia in vitro. These similarities 
indicate that the abnormalities are, at least in part caused by direct and/or indirect 
effects of hyperglycaemia. 
 
The morphological changes found in vitro were associated with dysfunctional oxidative 
phosphorylation. After culture in hyperglycaemia there was a reduction in energy 
production. Hence there was a reduction in levels of ATP, of oxygen consumption tied 
to ATP production, signalling by Mito Tracker Red (a marker of active respiring 
mitochondria) as well as proteins of oxidative phosphorylation i.e. mitochondrial 
complexes I-IV. Interestingly complex V, (ATP synthase), the final enzyme in 
oxidative phosphorylation, was not affected and furthermore mitochondrial DNA in 
relation to nuclear DNA was increased and not decreased. This suggests that the effects 
of hyperglycaemia did not reflect unspecific toxicity. 
 
Culture in vitro at low glucose concentrations has shown adverse effects on islets [141]. 
Therefore we cultured islets in 11 or 27 mmol/l glucose. 
 
Mitochondrial morphology has been studied in other animal models of diabetes. In 
Goto-Kakizaki (GK) rats, a spontaneous non-obese type 2 diabetes animal model, an 
increased number of mitochondria have been reported, coupled with a decrease in size 
[142]. These differences compared to our results could be explained by beta cell 
specific genetic factors in GK rats compared to the hyperglycaemia effects per se that 
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was studied by us. However when GK rats were challenged with sucrose [143], the 
morphological abnormalities were similar to the ones found in the present study. 
Another diabetic animal model, without beta cell specific genetic influence, is the 
insulin resistant MKR mouse model. Studies in this animal model show (similar to us) 
a decreased number and increased size of mitochondria [144]. Perhaps the increased 
demands of insulin in the insulin resistant animal model and the hyperglycaemia in our 
study are comparable with regard to the morphological effects we detect on 
mitochondria. 
 
In light of our observation of megamitochondria we looked at a key protein involved in 
the fusion process of mitochondria, namely OPA1 [30, 31]. We observe a decrease 
rather than an increase in OPA1 in hyperglycaemia. This would seem negate OPA1 as a 
driver in the process that results in megamitochondria. Possibly megamitochondria are 
instead formed by the inhibition of fission, however we did not study fission related 
proteins. 
 
The beneficial effects of tifenazoxide in our in vivo diabetes model are in line with 
beneficial ones on insulin secretion using a very similar protocol [92]. KATP-channel 
openers (tifenazoxide or diazoxide) can protect glucose induced insulin secretion by 
alleviating mitochondrial dysfunction. Further studies on the molecular mechanisms 
behind the beneficial effect of tifenazoxide have been hampered by unavailability of the 
drug for supplemental in vitro investigations. Also experiences with diazoxide indicate 
that the drug is unsuitable for longer term of culture in vitro (results not shown). Hence 
the molecular mechanisms behind the drug induced beneficial effects remain to be 
investigated. 
 
The clinical relevance and significance of our findings is that even moderately 
increased hyperglycaemia (similar to type 2 diabetes patients) can exert marked 
influence on mitochondria. 
 
5.3 PAPER III 
This study shows that the CD36 transporter in insulin-producing cells is functioning for 
facilitated fatty acid transport. Overexpression of CD36 induces functional effects on 
glucose-induced insulin secretion and on fatty acid metabolism. 
 
We find (by immunofluorescence and western blot on subcellular fractions) that 
overexpression of CD36 protein was mainly localised in the plasma membrane. This is 
in line with studies in other cells which show that CD36 can be recruited to the plasma 
membrane from intracellular depots [145-147]. From the subcellular fractions we 
detected a week signal for CD36 (by western blot) in secretory granules which would 
agree with data from Noushmehr et al. [40] which detected CD36 in insulin granules in 
human islets of Langerhans. At the time of publication of paper III we were unable to 
detect a signal for CD36 by western blot in non-induced cells. However, as shown in 
results of paper IV, improvements of western blot technique now allow us to have a 
signal also for the non-induced cells. Nevertheless, our findings of localisation of CD36 
were limited to CD36 overexpressing cells, hence confirmatory studies on CD36 
localisation in non-induced cells, native beta-cells or INS-1 cells could be of interest. 
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Even with our considerable overexpression of CD36 protein we found only modest 
effects on fatty acid metabolism and glucose-induced insulin secretion. Possibly 
cellular adaptations come into play which reduces the impact of increased uptake of 
fatty acids. Overexpressing CD36 increased fatty acid uptake by approximately 40%. 
However, overexpression of CD36 also enhanced fatty acid efflux which could be one 
of these cellular adaptations. Such enhanced efflux was shown in another cell type with 
overexpression of CD36 [148]. This could be by mechanisms of passive diffusion. 
 
The most apparent functional effect by CD36 overexpression was the loss of normal 
potentiation of glucose-induced insulin secretion by acute addition of fatty acids. 
Palmitate enhanced glucose-induced insulin secretion more than oleate in the non-
induced cells, which is in line with previous studies [21]. Therefore the inhibited 
potentiation was more apparent in experiments with palmitate than oleate. Evidence for 
the specificity of a CD36 overexpression effect was strengthened by normal fatty acid 
potentiation of glucose-induced insulin secretion in tet-on cells lacking the coupling to 
CD36. 
Mechanisms behind the effects of CD36 overexpression on insulin secretion may partly 
be related to the modest alterations in fatty acid oxidation that were observed. Normally 
glucose, via malonyl-CoA inhibits fatty acid oxidation by allosteric inhibition of CPT1 
[149]. CD36 overexpression attenuated the inhibitory effect of glucose on fatty acid 
oxidation and CPT1 activity. Hence a deficient accumulation of malonyl-CoA or 
alternatively a reduced effect of this CPT1 inhibitor could play a role for the CD36-
induced metabolic abnormality. This could lead to reduced accumulation of fatty acid 
derived signalling molecules [150]. It has been shown that a mutation in the CPT1 
enzyme rendered the enzyme resilient to malonyl-CoA inhibition which led to 
decreased glucose induced insulin secretion [151]. 
 
Measurements of triglyceride stores and visual inspection of Oil-red O showed only 
moderate effects of CD36 on lipid accumulation. Furthermore, TLC data showed no 
increased incorporation of lipids by CD36 overexpression, suggesting that lipid 
accumulation would not cause the functional effects that we found. 
 
Further, we found no structural damage (by the parameters; mitochondrial mass, ROS, 
or apoptosis) linked to increased uptake of fatty acids which could explain the 
functional effects. 
 
Conclusively, CD36 overexpression increase uptake of fatty acids but also increases 
efflux of fatty acids. This futile transport of fatty acids could be thought to negatively 
affect the functional interplay between glucose and fatty acids on insulin secretion and 
fatty acid metabolism. 
 
5.4 PAPER IV 
This study shows that overexpressing CD36 in an insulin secreting cell line specifically 
enhances the uptake of FITC-labelled oxLDL and that this effect correlates with the 
extent of overexpression. In other cell types CD36 showed the highest affinity for 
oxLDL compared to other scavenging receptors that internalized oxLDL [152]. While 
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CD36 appears to be an important receptor for scavenging of oxLDL the importance of 
other scavenging receptors of oxLDL in vivo in beta cells is as yet uncertain. 
 
OxLDL levels are elevated in type 2 diabetes patients and increase with duration of the 
disease [98]. Our results that oxLDL up-regulated the CD36 protein levels and that 
there was a dose-dependent relationship between degree of CD36 overexpression and 
resulting FITC-oxLDL accumulation suggests importance of the transporter during 
physiological and pathophysiological conditions. Our finding that also nLDL up-
regulated CD36 can possibly be explained by formation of a significant amount of 
oxLDL during the 48 h period of culture [153]. 
 
We found that oxLDL dose-dependently decreases viability, measured by MTT, 
apoptosis and LDH release. Notably, these effects were independent of CD36 protein 
levels and uptake of FITC-oxLDL. Similarly, oxLDL dose-dependently decreased 
function, as assessed from glucose-induced insulin secretion, independently of CD36 
protein levels and uptake of FITC-oxLDL.  This discrepancy between FITC-oxLDL 
uptake and effect on viability and function can be explained by only modestly increased 
intracellular content of cholesterol, revealed by experiments of the uptake of 
3
H 
cholesterol labelled oxLDL. Furthermore, there were no histological signs of lipid 
accumulation visualised by oil red O. Nor was the cell size increased as assessed from 
FACS data. Taking into account that FITC labels the protein part of LDL i.e. ApoB100, 
and that tritium (
3H) is incorporated into the LDL’s cholesterol part, our results suggest 
that CD36 overexpressing cells on the one hand continuously enhance the uptake of 
oxLDL, recorded as the increased FITC accumulation over time, while on the other 
hand cells efficiently efflux cholesterol. Our data thus suggest that these insulin 
producing cells have efficient cholesterol efflux machinery that counteracts extensive 
lipid intracellular accumulation. 
 
We found evidence of oxLDL toxicity with increasing concentrations of this 
lipoprotein, which is in line with studies using other types of cells [154]. Previous 
studies in rat pancreatic islet beta cells found no toxicity with increasing oxLDL 
concentration in the range of 0-25 µg/ml [100]. This discrepancy could be explained by 
concentrations tested, different cell types (INS-1 vs. primary rat beta cells), differences 
in culture conditions (FBS vs. BSA) or differences in oxLDL preparations. Our data 
indicate that toxic and functional effects of oxLDL do not require internalisation, and 
suggest that negative effects may come about due to extracellular receptor interactions. 
In fact, others have shown that deleterious effects of oxLDL may occur on the cell 
surface, such as formation of cytotoxins [155]. Extracellular effects could be exerted by 
a multitude of receptors which have been demonstrated in other tissues [156]. 
Interactions with such receptors can have negative effects [156]. 
 
We note that FITC-labelled products remain intracellular over a prolonged period of 
time. This suggests that the protein part of LDL, ApoB100, is not rapidly processed by 
INS-1 cells. It has been shown recently that ApoB100 derived peptides can influence 
innate and adaptive immune responses [157, 158]. Whether intracellular accumulation 
of ApoB100 can influence beta cell function remains to be investigated. 
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Some limitations to this study should be stated. The preparation method for oxLDL that 
we have used has been standardized and used in numerous studies during the last 
decades. However we cannot rule out that other modification pathways, i.e. by HOCl, 
chloramines, phenoxyl radical intermediates and peroxynitrate may generate other 
forms of oxLDL with different bioactivities. Moreover, this study is performed with 
INS-1 cells; hence ideally results should be confirmed in native beta cells.  Furthermore 
oxidative modifications in vivo may differ from those that are here induced by copper. 
 
5.5 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
Type 2 diabetes is a disease affecting many people in the world causing suffering and 
serious complications. With the extensive on-going research in vast different areas the 
knowledge about the disease is increasing; however the complexity of the disease has 
proven to be a difficult puzzle to solve. 
Diabetes is thus a disease influenced by many factors and multiple genes. Therefore 
there are numerous mechanisms that can disturb the normally fine-tuned balance of 
glucose homeostasis. The loss of metabolic control that occurs in type 2 diabetes is 
detrimental for the progression of the disease. Hence early diagnose and treatment is 
important for preventing progression and complication of the disease. This thesis aimed 
to highlight some of the nutritional and dysmetabolic factors that potentially play a role 
in type 2 diabetes. 
The adverse effects of hyperglycaemia are well studied but not fully elucidated. Beta 
cell metabolism appears to be a major player in these effects. Hyperglycaemia is often 
accompanied by dyslipidaemia which has emerged as an important target to treat as the 
risk for cardiovascular disease is increased in prediabetes and diabetes subjects. 
We show that low intake of wholegrain increases the risk for developing abnormal 
glucose tolerance. Interesting studies for the future would be an intervention study to 
test if prediabetes subjects can reverse to normal glucose tolerance by increasing their 
intake of wholegrain. Other interesting studies would of course be to find molecular 
mechanisms for the effects of wholegrain intake. 
Dyslipidaemia is a dysmetabolic factor with potential effects on type 2 diabetes. With 
our CD36 overexpressing INS-1 cell line we wanted to study the effects of increased 
uptake of fatty acids and oxLDL. Increased uptake of fatty acids and oxLDL shows 
negative effects on glucose-induced insulin secretion. The accumulation of lipids was 
however modest which would suggest that an efficient efflux system is present in the 
cells. Future studies in regulation of the efflux system could be of interest. 
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6 CONCLUSIONS 
 
 Low consumption of wholegrain products carries increased risk for 
deteriorating glucose tolerance, especially progression from NGT to 
prediabetes. Furthermore, we add evidence for effect modification by 
polymorphisms of the TCF7L2 gene. 
 Moderate hyperglycaemia induces morphological aberrations of beta cell 
mitochondria which can be replicated by long-term exposure to elevated 
glucose in vitro. These aberrations are then associated with dysfunction of 
oxidative phosphorylation. 
 CD36 overexpression increases uptake of fatty acids but also increases efflux 
of fatty acids. This seemingly futile transport of fatty acids may affect the 
functional interplay between glucose and fatty acids on insulin secretion and 
fatty acid metabolism. 
 CD36 specifically scavenges oxLDL into INS-1 cells; however the increased 
CD36 dependent uptake of oxLDL did not enhance toxicity and did not 
aggravate negative functional effects. Instead our data indicate that efficient 
intracellular cholesterol efflux machinery is present to balance increased 
uptake. 
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